Gynaecological cancer group

Summary

The Gynaecological cancer group is a multidisciplinary team made up of gynaecologists, oncologists, pathologists and basic researchers. The group has three leaders: Xavier Matias-Guiu, who also leads the CIBER group (CB16 / 12/00231, in collaboration with IRBLLEIDA), Jordi Ponce, Mireia Martin-Satué, David Llobet and Ruth Rodriguez-Barrueco. The group has just started working in collaboration with different areas of gynecological cancer.

867 Publications

mucinous_lmp_ovarian_tumour_intermed_mag

Strategic lines

Selected Publications

Kim,TW;Bedard,PL;Lorusso,P;Gordon,MS;Bendell,J;Oh,D;Ahn,MJ et al, Anti-TIGIT Antibody Tiragolumab Alone or With Atezolizumab in Patients With Advanced Solid Tumors A Phase 1a/1b Nonrandomized Controlled Trial, JAMA Oncol., 2023;9(11):1574-1582, doi:10.1001/jamaoncol.2023.3867
Crosas Molist,E;Graziani,V;Maiques,O;Pandya,P;Monger,J;Samain,R;George,SL et al, AMPK is a mechano-metabolic sensor linking cell adhesion and mitochondrial dynamics to Myosin-dependent cell migration., Nat. Commun., 2023;14(1):2740-2740, doi:10.1038/s41467-023-38292-0
Samain,R;Maiques,O;Monger,J;Lam,H;Candido,J;George,S;Ferrari,N et al, CD73 controls Myosin II-driven invasion, metastasis, and immunosuppression in amoeboid pancreatic cancer cells, Sci. Adv., 2023;9(42):doi:10.1126/sciadv.adi0244
Costas,L;Onieva,I;Pelegrina,B;Marin,F;Carmona,A;López Querol,M;Frias Gomez,J et al, Evaluation of Somatic Mutations in Urine Samples as a Noninvasive Method for the Detection and Molecular Classification of Endometrial Cancer, Clin. Cancer Res., 2023;29(18):3681-3690, doi:10.1158/1078-0432.CCR-23-0367
Espinosa Sotelo,R;Fuste,NP;Penuelas Haro,I;Alay,A;Pons,G;Almodovar,X;Albaladejo,J et al, Dissecting the role of the NADPH oxidase NOX4 in TGF-beta signaling in hepatocellular carcinoma, Redox Biol., 2023;65102818-102818, doi:10.1016/j.redox.2023.102818

Selected Projects

17ACL120. A PHASE IA/B OPEN-LABEL, DOSE-ESCALATION STUDY OF THE SAFETY AND PHARACOKINETICS OF MTIG7192A AS A SINGLE AGENT AND INCOMBINATION WITH ATEZOLIZUMAB IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC TUMORS. Genentech, Inc.. Budget: 619.866€. 2017- . PI: Gil Martin, Marta.
19ACL209. ESTUDIO DE FASE 1, ABIERTO, MULTICÉNTRICO Y DE VARIOS GRUPOS DE MK-4830 EN MONOTERAPIA Y EN COMBINACIÓN CON PEMBROLIZUMAB EN PARTICIPANTES CON TUMORES SÓLIDOS AVANZADOS. MERCK SHARP & DOHME ESPAÑA S.A. Budget: 521.875€. 2019- . PI: Gil Martin, Marta.
19PSJ014. TARGETING THE AUTORESISTOME AS A NEW THERAPEUTIC STRATEGY IN ENDOMETRIAL CANCER. Asociación Española Contra el Cáncer (AECC). Budget: 299.849,22€. 2019-2023. PI: LLOBET NAVAS, DAVID.
2023-151-1. ESTUDIO TIPO CESTA DE FASE 1B/2, MULTICÉNTRICO Y ABIERTO QUE EVALÚA LA SEGURIDAD Y EFICACIA DE BEMARITUZUMAB EN MONOTERAPIA EN TUMORES SÓLIDOS CON SOBREEXPRESIÓN DE FGFR2B (FORTITUDE-301). Amgen, S.A.. Budget: 240.251€. 2023- . PI: Gil Martin, Marta.
18ACL156. ESTUDIO DE FASE I, ABIERTO, MULTICÉNTRICO, DE BÚSQUEDA DE DOSIS DE TNO155 ORAL EN PACIENTES ADULTOS CON TUMORES SÓLIDOS AVANZADOS. Novartis Farmacéutica, S.A.. Budget: 233.522€. 2018- . PI: Gil Martin, Marta.

More Information

The group currently has projects under way which are funded by ISCIII, MINECO and private organisations (Merck-Serono, MSD), as well as a good track record of publications in peer-reviewed journals.

CULTIVOS 3D PERSONALIZADOS PARA SELECCIÓN DE TRATAMIENTO PARA PACIENTES DE CÁNCER EN MEDICINA DE PRECISIÓN (PROYECTO 3D-ID)
PI: Matias-Guiu, Xavier
Convocatoria Retos Colaboración, expediente: RTC-2017- 6573-1
Coordinador: STEMTEK THERAPEUTICS, S.L.
Ministerio de Ciencia, Innovación y Universidades, perteneciente a la Agencia Estatal de Investigación (AEI).
Cofinanciado por el Fondo Europeo de Desarrollo Regional. FEDER, una manera de hacer Europa. Promover el desarrollo tecnológico, la innovación y una investigación de calidad.